Shining a Light on Lipid Nanoparticle Characterization
Publication
Article
BioPharm InternationalBioPharm International, Emerging Therapies September 2022
Volume 2022 eBook
Issue 3
Pages: 22–25
Using an orthogonal approach to lipid nanoparticle analysis can increase the odds of project success.
Likanaris/Stock.adobe.com
The complexity of messenger RNA (mRNA)-based therapeutics is evident in the lipid nanoparticles (LNPs) used to encapsulate fragile mRNA cargo. Size, composition, aggregation, surface charge, and structure of LNPs can all have significant effects on a therapeutic molecule’s success. Unlike small-molecule drugs or protein therapeutics, which are chemically or biologically synthesized, LNPs self-assemble during the mixing of their component ingredients. This article discusses the challenges of LNP characterization as well as the analytical techniques that have proven successful in optimizing their development.
Read this article in BioPharm International’s September 2022 Emerging Therapies 2022 eBook.
About the authors
Hanna Jankevics Jones, PhD, and Natalia Markova, PhD, are pharmaceutical segment marketing managers at Malvern Panalytical.
Article Details
BioPharm International
eBook: Emerging Therapies 2022, September 2022
September 2022
Pages: 22–25
Citation
When referring to this article, please cite it as H.J. Jones and N. Markova, “Shining a Light on Lipid Nanoparticle Characterization," BioPharm International Emerging Therapies 2022 eBook (September 2022).
Articles in this issue
Treating Cancer with Oncolytic Viruses
Accelerating the Development of mRNA Therapeutics
Real-Time Post-Apheresis Documentation Decreases Errors
Shining a Light on Lipid Nanoparticle Characterization
The Road to Personalized Medicine: Reimagining Drug Manufacturing
Novel Therapies of 2022
Biotech Incubators Cultivate a Global Scene
Recent Videos
Related Content
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Article
Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025Article
The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
